echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ann Oncol: OlympiAD's final overall survival and tolerance results

    Ann Oncol: OlympiAD's final overall survival and tolerance results

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    In the OlympiAD study, olapani was shown to improve progressive survival metastatic breast cancer (mBC) compared to chemotherapy with a reproductive BRCA1 and/or BRCA2 mutation (BRCAAm) and a human epidermal growth factor receptor 2 (HER2) negative chemotherapy (TPC)Now, we report the program's final overall survival (OS) results and describe the most common adverse events (AE) to better understand the population's tolerance to olaparib
    OlympiAD is a Phase III randomized, controlled, open-label study (NCT020006222) in patients with BRCAm reproductive and HER2-negative mBC lines who received mBC chemotherapy with a line of 2Patients were randomly divided into olapani tablets (300 mg bid) or pre-announced TPC (Capitabin, Changchun Rybin or Ayrebrin)OS and security are secondary endpoints
    Results A total of 205 patients were randomly assigned to olaparib and 97 were randomly assigned to TPCAt 64% of the data maturity, Olapani's median OS was 19.3 months, while the median OS for TPC was 17.1 months (HR 0.90, 95%CI 0.66-1.23; P - 0.513); In a pre-specified subgroup, HR using olaparib and TPC for OS is: past mBC chemotherapy (no (first-line treatment): 0.51, 95% CI 0.29-0.90; (Triple negative: 0.93, 0.62-1.43; hormone receptor-positive: 0.86, 0.55-1.36); previous platinum (yes: 0.83, 0.49-1.45; No: 0.91, 0.64-1.33)Adverse events during olapani treatment are usually low and can be controlled by supporting treatment or dose adjustmentThe discontinuation rate is very low (4.9%) and long-term use of olapani does not increase the risk of anaemia
    Overall, the results suggest that, while OS did not show statistically significant improvement compared to TPC, OS may have a meaningful OS benefit in patients who did not receive chemotherapy for metastatic diseaseOlaparib is generally well tolerated and there is no evidence of cumulative toxicity from prolonged exposure
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.